Illumina EBITDA
¿Qué es el EBITDA de Illumina?
El EBITDA de Illumina, Inc. es $570.000M
¿Cuál es la definición de EBITDA?
El EBITDA es la ganancia de una compañía antes de intereses, impuestos, depreciación y amortización y es una medida contable calculada usando las ganancias netas de la compañía, antes de que se resten los gastos de interés, los impuestos, la depreciación y la amortización, como un proxy de la rentabilidad operativa actual de la compañía.
Although EBITDA is not a financial measure recognized in generally accepted accounting principles, it is widely used in many areas of finance when assessing the performance of a company, such as securities analysis. It is intended to allow a comparison of profitability between different companies, by discounting the effects of interest payments from different forms of financing (by ignoring interest payments), political jurisdictions (by ignoring tax), collections of assets (by ignoring depreciation of assets), and different takeover histories (by ignoring amortization often stemming from goodwill). EBITDA is a financial measurement of cash flow from operations that is widely used in mergers and acquisitions of small businesses and businesses in the middle market. It is not unusual for adjustments to be made to EBITDA to normalize the measurement allowing buyers to compare the performance of one business to another.
EBITDA de compañías en Sector Miscellaneous en LSE en comparadas con Illumina
¿Qué hace Illumina?
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has collaboration agreements with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer; LetsGetChecked to track COVID-19 variants in California; and Merck & Co., Inc. to develop and commercialize tests that identify genetic mutations used in the assessment of homologous recombination deficiency. The company was incorporated in 1998 and is headquartered in San Diego, California.
Empresas con ebitda similar a Illumina
- South Jersey Industries tiene EBITDA de $569.154M
- Neurocrine Biosciences tiene EBITDA de $569.400M
- REA tiene EBITDA de AUD$569.400M
- Federal-Mogul Goetze (India) tiene EBITDA de ₨569.657M
- Singapore Exchange tiene EBITDA de SGD$569.841M
- Advantage Oil & Gas tiene EBITDA de CAD$569.886M
- Illumina tiene EBITDA de $570.000M
- Pix Transmissions tiene EBITDA de ₨570.008M
- PTL Enterprises tiene EBITDA de ₨570.083M
- Zhejiang Jianye Chemical Co tiene EBITDA de ¥570.276M
- Thor Industries tiene EBITDA de $570.757M
- Venus Remedies tiene EBITDA de ₨571.085M
- Medibank Private tiene EBITDA de AUD$571.200M